Medidata announced that Rho, is using Medidata to standardize its clinical trial platform for building out its decentralized clinical trial (DCT) technology offerings. This will enable Rho to provide rapid reporting of cross-domain, cross-study data in decentralized trials, where data collection methods have become more numerous, varied, and complex. Rho made the strategic decision to invest in Medidata’s single platform to provide flexible and agile support for future business growth. This clinical technology capability and expertise will advance efforts to accelerate sponsors’ clinical development programs by giving them complete access to their clinical and operational data and enhancing its utilization to inform decision-making. Medidata’s end-to-end platform helps its clients attract and win more sponsor bids, while reducing study build time, saving money on unexpected data migrations and transfers, and speeding up data reconciliation and cleanup.